| Field | Specification |
|---|---|
| Target | |
| Alternative names | Nitric oxide synthase, endothelial; Constitutive NOS; Cnos; EC-NOS; Endothelial NOS; eNOS; NOS type III; NOSIII; NOS3 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human eNOS/NOS3 recombinant protein (Position: P34-Q1153). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets nitric oxide synthase 3 (gene NOS3) in human samples and is validated for Western blot, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 133.3 kDa, and the supplier reports an observed band at about 140 kDa.
Endothelial nitric oxide synthase (eNOS, NOS3) produces nitric oxide in blood vessel endothelium. Nitric oxide diffuses to smooth muscle and relaxes it through cGMP signaling, and it also supports VEGF-driven angiogenesis and affects platelet function. eNOS activity and phosphorylation are widely studied in vascular biology, blood pressure regulation and endothelial dysfunction.
| Target | Nitric oxide synthase 3 (gene NOS3; UniProt P29474, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 133.3 kDa |
| Observed MW | 140 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human placenta tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (ICC/IF): U2OS cells.
Samples with a confirmed signal (flow cytometry): U937 cells.
Immunogen
Recombinant human eNOS/NOS3 fragment (Pro34–Gln1153), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places nitric oxide synthase 3 in the cell membrane, membrane, cytoplasm and Golgi apparatus. Tissue expression noted by UniProt (human): Platelets, placenta, liver and kidney. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Lin Zhen et al. (2003) Nitric oxide synthase expression in human bladder cancer and its relation to angiogenesis. Urological Research. 10.1007/s00240-003-0302-9
